Kelcey A Bland1, Sarah E Neil-Sztramko2, Amy A Kirkham3, Alis Bonsignore4, Cheri L Van Patten5, Donald C McKenzie6, Karen A Gelmon5, Kristin L Campbell7,8. 1. Rehabilitation Sciences, University of British Columbia, 212-2177 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada. 2. Faculty of Health Sciences, McMaster University, 1280 Main St. W., Hamilton, ON, L8S 4K1, Canada. 3. Department of Biomedical Engineering, University of Alberta, 1098-8308-114 St., Edmonton, AB, T6G 2V2, Canada. 4. Toronto Rehabilitation Institute, University of Toronto, 190 Elizabeth St., Toronto, ON, M5S 2C9, Canada. 5. British Columbia Cancer Agency, 600 W. 10th Ave, Vancouver, BC, V5Z 4E6, Canada. 6. School of Kinesiology, University of British Columbia, 210-6081 University Boulevard, Vancouver, BC, V6T 1Z1, Canada. 7. Rehabilitation Sciences, University of British Columbia, 212-2177 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada. kristin.campbell@ubc.ca. 8. Department of Physical Therapy, University of British Columbia, 212-2177 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada. kristin.campbell@ubc.ca.
Abstract
PURPOSE: While exercise is associated with numerous benefits in women with breast cancer, adherence to exercise training concurrent to cancer treatment is challenging. We aimed to identify predictors of attendance to an oncologist-referred exercise program offered during and after adjuvant breast cancer treatment. METHODS: Women with early-stage breast cancer receiving chemotherapy (n = 68) enrolled in the Nutrition and Exercise During Adjuvant Treatment (NExT) study. Supervised aerobic and resistance exercise was prescribed three times per week during treatment, then one to two times per week for 20 additional weeks. Predictors of attendance were identified using multivariate linear regression for three phases of the intervention, including during (1) adjuvant chemotherapy, (2) radiation, and (3) 20-weeks post-treatment. RESULTS: Higher baseline quality of life (QoL) predicted higher attendance during chemotherapy (β = 0.51%, 95 CI: 0.09, 0.93) and radiation (β = 0.85%, 95 CI: 0.28, 1.41), and higher QoL, measured at the end of treatment, predicted higher attendance post-treatment (β = 0.81%, 95 CI: 0.34, 1.28). Being employed pre-treatment (β = 34.08%, 95 CI: 5.71, 62.45) and a personal annual income > $80,000 (β = 32.70%, 95 CI: 0.85, 64.55) predicted higher attendance during radiation. Being divorced, separated or widowed (β = - 34.62%, 95 CI: - 56.33, - 12.90), or single (β = - 25.38%, 95 CI: - 40.64, - 10.13), relative to being married/common-law, and undergoing a second surgery (β = - 21.37%, 95 CI: - 33.10, - 9.65) predicted lower attendance post-treatment. CONCLUSIONS: Demographic variables, QoL, and receipt of a second surgery significantly predicted attendance throughout the NExT supervised exercise program. These results may help identify individuals with exercise adherence challenges and improve the design of future interventions, including optimizing the timing of program delivery.
PURPOSE: While exercise is associated with numerous benefits in women with breast cancer, adherence to exercise training concurrent to cancer treatment is challenging. We aimed to identify predictors of attendance to an oncologist-referred exercise program offered during and after adjuvant breast cancer treatment. METHODS:Women with early-stage breast cancer receiving chemotherapy (n = 68) enrolled in the Nutrition and Exercise During Adjuvant Treatment (NExT) study. Supervised aerobic and resistance exercise was prescribed three times per week during treatment, then one to two times per week for 20 additional weeks. Predictors of attendance were identified using multivariate linear regression for three phases of the intervention, including during (1) adjuvant chemotherapy, (2) radiation, and (3) 20-weeks post-treatment. RESULTS: Higher baseline quality of life (QoL) predicted higher attendance during chemotherapy (β = 0.51%, 95 CI: 0.09, 0.93) and radiation (β = 0.85%, 95 CI: 0.28, 1.41), and higher QoL, measured at the end of treatment, predicted higher attendance post-treatment (β = 0.81%, 95 CI: 0.34, 1.28). Being employed pre-treatment (β = 34.08%, 95 CI: 5.71, 62.45) and a personal annual income > $80,000 (β = 32.70%, 95 CI: 0.85, 64.55) predicted higher attendance during radiation. Being divorced, separated or widowed (β = - 34.62%, 95 CI: - 56.33, - 12.90), or single (β = - 25.38%, 95 CI: - 40.64, - 10.13), relative to being married/common-law, and undergoing a second surgery (β = - 21.37%, 95 CI: - 33.10, - 9.65) predicted lower attendance post-treatment. CONCLUSIONS: Demographic variables, QoL, and receipt of a second surgery significantly predicted attendance throughout the NExT supervised exercise program. These results may help identify individuals with exercise adherence challenges and improve the design of future interventions, including optimizing the timing of program delivery.
Entities:
Keywords:
Adjuvant chemotherapy; Breast neoplasm; Exercise training; Radiation; Resistance training
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Helen M Milne; Karen E Wallman; Andrew Guilfoyle; Sandy Gordon; Kerry S Corneya Journal: J Sport Exerc Psychol Date: 2008-02 Impact factor: 3.016
Authors: Hannah Arem; Mia Sorkin; Brenda Cartmel; Martha Fiellin; Scott Capozza; Maura Harrigan; Elizabeth Ercolano; Yang Zhou; Tara Sanft; Cary Gross; Kathryn Schmitz; Tuhina Neogi; Dawn Hershman; Jennifer Ligibel; Melinda L Irwin Journal: J Cancer Surviv Date: 2016-01-19 Impact factor: 4.442
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Amy A Kirkham; Cheri L Van Patten; Karen A Gelmon; Donald C McKenzie; Alis Bonsignore; Kelcey A Bland; Kristin L Campbell Journal: Oncologist Date: 2017-10-05
Authors: Daniel Y T Fong; Judy W C Ho; Bryant P H Hui; Antoinette M Lee; Duncan J Macfarlane; Sharron S K Leung; Ester Cerin; Wynnie Y Y Chan; Ivy P F Leung; Sharon H S Lam; Aliki J Taylor; Kar-keung Cheng Journal: BMJ Date: 2012-01-30
Authors: Caroline S Kampshoff; Femke Jansen; Willem van Mechelen; Anne M May; Johannes Brug; Mai J M Chinapaw; Laurien M Buffart Journal: Int J Behav Nutr Phys Act Date: 2014-07-02 Impact factor: 6.457
Authors: Dominic O'Connor; Matilde Mora Fernandez; Gabriel Signorelli; Pedro Valero; Brian Caulfield Journal: Support Care Cancer Date: 2019-02-08 Impact factor: 3.603
Authors: Cristina Roldán-Jiménez; Bella Pajares; Sofía Ruiz-Medina; Manuel Trinidad-Fernández; Manuel González-Sánchez; Nuria Ribelles; José Manuel García-Almeida; María José Ríos-López; Emilio Alba; Antonio Ignacio Cuesta-Vargas Journal: Support Care Cancer Date: 2021-08-31 Impact factor: 3.359
Authors: Teresa Paolucci; Andrea Bernetti; Marco Paoloni; Serena V Capobianco; Arianna V Bai; Carlo Lai; Laura Pierro; Monica Rotundi; Carlo Damiani; Valter Santilli; Francesco Agostini; Massimiliano Mangone Journal: Biores Open Access Date: 2019-07-03
Authors: Lenja Witlox; Miranda J Velthuis; Jennifer H Boer; Charlotte N Steins Bisschop; Elsken van der Wall; Wout J T M van der Meulen; Carin D Schröder; Petra H M Peeters; Anne M May Journal: PLoS One Date: 2019-05-08 Impact factor: 3.240
Authors: Emily R Dunston; Yang Bai; Maria Newton; Leslie Podlog; Darren Walker; Sonal Oza; Rebecca W Zingg; Pamela A Hansen; Adriana M Coletta Journal: Integr Cancer Ther Date: 2022 Jan-Dec Impact factor: 3.077